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The importance of early initiation of inhaled steroids even in mild asthma has been documented in several studies.
It is not, however, clear whether the treatment should be started with a high or a low dose of the inhaled steroid. We
have compared the eects of high and low dose inhaled steroid, budesonide, in patients with newly detected asthma.
We studied 101 adult patients with newly detected bronchial asthma who were without inhaled steroid or any
regular pharmacological treatment for their asthma. The patients were randomly allocated to two treatment
groups: one to receive 800mg inhaled budesonide per day and the other to receive 200mg inhaled budesonide per
day. The drugs were given with a Turbuhaler1 dry powder inhaler. During the 3-month treatment period, no
significant dierences between the treatment groups were noted in morning or evening PEF values, in spirometric
parameters, in asthmatic symptoms or in the use of rescue b2-agonists. The decrease in bronchial hyper-
responsiveness was, however, more marked in the high dose budesonide group, reaching a borderline significance
(P=0?10 high vs. low dose budesonide). In addition, in serum markers of asthmatic inflammation significant
dierences were shown between the treatment groups. The decrease in the number of blood eosinophils during the
treatment was more marked in the high dose budesonide group (P=0?02; high vs. low dose budesonide). In serum
ECP no change was observed in the low dose budesonide group, but a marked decrease in the high-dose budesonide
group (P=0?008; high vs. low dose budesonide). The change was even more marked with regard to serum EPX
(P=0?005; high vs. low dose budesonide).
Our results support the view that the treatment of newly detected asthma should be started with a high dose of
inhaled steroid. The low dose may not be enough to suppress asthmatic inflammation despite good clinical primary
response.
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Airway inflammation is the basic underlying pathophysio-
logical mechanism in bronchial asthma, and anti-inflam-
matory treatment with inhaled corticosteroids has been
advocated as the first line treatment in mild newly detected
asthma (1). However, there exists controversy whether the
treatment should be started with a high dose of inhaledReceived 1 July 1999 and accepted in revised form 12 January 2000.
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0954-6111/00/070678+06 $35?00/0steroid or if the same eect could be attained with a low
dose. British guidelines emphasize the importance of
gaining initial control of asthma, which may mean starting
the treatment with a high dose of inhaled steroid and then
stepping down (2). However, in a recent study by van der
Molen et al. the same clinical response was attained
whether the treatment was started with a high or low dose
of inhaled steroid (3).
We have conducted a study in which we compared the
ecacy of high and low dose of inhaled budesonide as the
initial treatment in newly detected asthma in patients who
had no previous regular pharmacological treatment for
their asthma.# 2000 HARCOURT PUBLISHERS LTD
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STUDY DESIGN
The study was performed as a randomized parallel group,
double-blind study, comparing two doses of inhaled
budesonide during a study period of 12 weeks. During a
run-in period of 1 week, the patients’ compliance and
capacity to take part in the study were assessed. No
intervention in asthma therapy was allowed during the run-
in period. At the end of the run-in period, the patients were
randomized using a computer program to one of the two
treatments in balanced blocks of four.
STUDY PROTOCOL
The investigational drugs were either high dose (800 mg) or
low dose (200 mg) inhaled budesonide (Pulmicort Turbu-
haler1, Astra Draco, Lund, Sweden). Two types of
Pulmicort Turbuhaler1 dry powder inhalers were used:
one containing budesonide 400 mg dose71 and the other
100 mg dose71. The daily number of inhalations was
constant: one inhalation twice daily. The patients were
allowed to use terbutaline from a dry powder inhaler
(250mg dose71 ) as a rescue medication. If prior to the
study the patient had used inhaled salbutamol as a powder
or pressurized metered-dose inhaler, this was permitted.
PATIENTS
One hundred and one adult (18 years or older) patients with
newly detected bronchial asthma (asthma diagnosed during
the last 3 months preceding the study and symptoms
presenting for less than 6 months) were randomized into the
study. Of the 105 subjects who were enrolled into the study,
four discontinued before randomization. All the patients
had to be without regular pharmacological treatment for
their asthma and they were allowed only short-acting
inhaled b2-agonist for rescue treatment. All the patients
fulfilled the criteria of asthma by ATS (4). In addition, only
patients with bronchial hyper-reactivity revealed by hista-
mine inhalation challenge (PC20 FEV18mg ml71) were
accepted into the study.
Signed consent was obtained from all patients. The study
was approved by the Ethics Committee of Kuopio
University Hospital.
CLINICAL AND LABORATORY
ASSESSMENTS
During the run-in period and the subsequent 12 weeks, the
patients recorded their peak expiratory flow rates (PEF)
before they took their medication in the morning and
evening (Mini Wright Peak Flow Meter, Clement Clark
International, London, U.K.) their use of supplemental
medication and adverse reactions. They also recorded their
symptoms of asthma separately each day and night as a
single score from 0 to 3.Assessments at the clinic were carried out at the start of
the run-in period, the start of active treatment and then
after 2, 6 and 12 weeks of treatment. The visits included
flow-volume spirometry (Medikro 909 Spirometer, Medik-
ro Ltd, Kuopio, Finland), the check of diary card and
histamine inhalation challenge (at the start of the study and
then after 6 and 12 weeks of active treatment). In addition,
blood samples for the analyses of Hb, sedimentation rate,
leukocytes, total blood eosinophil count, S-ECP (serum
eosinophilic cationic protein), S-EPX (serum eosinophilic
protein X) and S-MPO (serum myeloperoxidase) were
drawn at the start of active treatment and thereafter at
every clinical visit.
The total eosinophil count was calculated by routine
dierential counting with a Coulter Counter (Coulter
STKS, Coulter Electronics Ltd, Luton, U.K.) S-ECP,
EPX and MPO were measured with a commercially
available radioimmunoassay research kits (Pharmacia
Diagnostics, Uppsala, Sweden). The sera were collected
and handled according to the manufacturer’s instructions
and stored at 7208C until analysed. The serum samples
from the same patient were analysed using the same kit.
ASSESSMENT OF BRONCHIAL
RESPONSIVENESS
Bronchial responsiveness was tested using a modification of
the method by Cockcroft et al. (5). The challenge with
solutions of histamine disphosphate in phosphate-buered
saline was carried out using a quantitative dosimetric
nebulization (Spira Elektro 2, Hengityshoitokeskus Ltd,
Ha¨meenlinna, Finland). The histamine was prepared in 10
doubling concentrations or dose steps 0?03, 0?06, 0?125,
0?25, 0?5, 1?0, 2?0, 4?0, 8?0 and 16 mg ml71). The challenge
began with nebulized saline and continued with progres-
sively higher concentrations of histamine. The patient
inhaled 30 nebulizations of each solution. The duration of
each nebulization was 0?4 sec. FEV1 was registered after 30
and 90 sec following each step of the challenge. The
challenge was terminated when a fall of 20% in FEV1
or a maximum concentration was achieved. On calculation
of the change, FEV1 after the inhalation of saline solution
was regarded as a reference value. PC20 FEV1 (histamine
concentration that caused a fall of 20% in FEV1) was
calculated from logarithmically transformed histamine
concentrations using linear interpolation between the last
two measurement points.
STATISTICAL METHODS
The sample size calculations were based on histamine PC20
FEV1. Assuming that the true dierence between groups is
one dose step and the standard deviation is 1?5 dose steps, it
was estimated that a sample size of 50 patients per group
has a 90% chance of detecting a statistically significant
dierence (significance level 0?05).
The data were analysed according to the All Patients
Treated (APT) approach for all variables. Single missing
values were replaced using the arithmetic mean of
680 H. TUKIAINEN ET AL.surrounding values, otherwise the Last Value Extended
(LVE) method was used.
For morning and evening PEF, and for other diary
variables, the weekly averages were calculated. For lung
function data, PC20 FEV1 and diary data, the primary
evaluation was performed by comparing the change from
baseline after 12 weeks of treatment. The change from
baseline was analysed by using t-test or by Mann–Whitney
U-test, when appropriate. Analysis of variance for repeated
measurements was carried out to test the changes (time
eect) in variables which were measured repeatedly during
the treatment period. PC20 FEV1 values were logarithmi-
cally transformed before analysis and are expressed as
geometric means and dose steps.
Laboratory variables of asthmatic inflammation were
logarithmically transformed before analysis and are ex-
pressed as geometric means. After 12 weeks of treatment.
The groups were compared using analysis of covariance
(ANCOVA), where the corresponding baseline was in-
cluded as a covariate.
All tests were two-sided and P-values 0?05 were
considered statistically significant.
Results
At the start of the study there were no statistically
significant dierences between the treatment groups except
for the dierence in sex distribution (male/female) (Table 1).
In the low dose budesonide group, 48/50 patients com-
pleted the study. One patient discontinued the study
because of traumatic contusion of the thorax and fractureTABLE 1. Characteristics of the patients at baseline
Characteristic Budes
(
Sex (M/F)
Age (yr) 37?
Smoking
never
ex-smoker
smoker
Atopy (yes/no)
Blood eosinophils (109 171) 0?2
FEV1 (1) 3?2
% of predicted* 88
FVC (1) 4?1
% of predicted* 93
PEF; morning (1min71) 4
% of predicted** 84
PC20FEV1
(mg ml71) (0?
Values are expressed as means+SEM or mean (range), with the e
as geometric means and ranges.
*Reference values were those of Viljanen et al. (6).
**Reference values were those of Nunn and Gregg (7).of a rib. Another patient was not able to complete the diary
correctly. In the high dose budesonide group 2/51, patients
were withdrawn because of errors in taking medicine.
LUNG FUNCTION AND BRONCHIAL
HYPER-RESPONSIVENESS
There was a statistically significant increase in FEV1 during
the treatment in both groups, but there were no statistically
significant dierences between the high and low dose
treatment groups (Table 2). FVC-values did not change
significantly during the treatments. In smokers, the
responses to treatment in FEV1 in both treatment groups
were significantly lower than those achieved in non-smokers
(P50?05).
Morning PEF-values rose from 85% (of predicted) to
91% (of predicted) during the 12-week treatment period in
the low dose budesonide group and from 84% (of
predicted) to 91% (of predicted) in the high dose
budesonide groups (time eect P50?0001; both groups)
(Fig. 1). There were also corresponding increases in the
evening PEF-values in both treatment groups (time eect
P50?0001; both groups) (Fig. 2). With respect to 12-week
changes in morning and evening PEF values, no significant
dierences between groups could be detected. The treat-
ment dierence is 1?1% (P=0?49, 95% CI72?1–4?3%) for
morning and 2?4% (P=0?10, CI 70?5–5?3%) for evening
PEF. Smokers had a significantly lower morning and
evening PEF-level, but overall responses to treatments were
similar in both smokers and non-smokers.
There was a significant decrease in bronchial hyper-
responsiveness in both treatment groups (time eectonide 200 mg
n=50)
Budesonide 800 mg
(n=51)
21/29 15/36
3 (18–68) 40?5 (19–62)
23 28
13 10
14 13
32/18 36/15
2 (0–0?9) 0?23 (0–1?1)
9+0?10 3?05+0?10
?0+1?44 86?7+1?44
7+0?14 3?93+0?12
?5+1?68 93?5+1?53
56+10 432+12
?9+1?61 83?8+1?58
1?50 1?44
18–7?76) (0?07–8?05)
xceptions of PC20 and blood eosinophils, which are presented
TABLE 2. Spirometric parameters, asthma symptom scores, use of b2-agonists and blood inflammatory markers at baseline and
after 3 months of treatment
200 mg budesonide 800 mg budesonide
Baseline 3 months Baseline 3 months
FEV1 88?0 89?7 86?7 88?3
(% of predicted) +1?4 +1?5 +1?4 +1?3
FVC 93?5 94?7 93?5 94?4
(% of predicted) +1?7 +1?4 +1?7 +1?4
Asthma symptom score (0–3)
Day 0?83
(91%)
0?34
(52%)
0?77
(82%)
0?30
(40%)
Night 0?32
(55%)
0?12
(25%)
0?39
(58%)
0?15
(22%)
Mean daily inhalation of b2-agonists
Day 1?03 0?41 1?02 0?34
Night 0?30 0?08 0?38 0?14
Blood eosinophils* (109 171) 0?22 0?19 0?23 0?14
S-ECP**(mg 171) 13?8 14?7 15?5 12?2
S-EPX*** (mg 171) 37?9 34?2 34?7 26?0
S-MPO****(mg171) 393 471 453 459
Spirometric parameters are expressed as means+SEM. Daily asthma symptom scores and use of b2-agonists are expressed as
means and blood indices as geometric means. Patients with symptoms of asthma (once or more per week) are presented in
parenthesis.
Dierence between treatment groups at 3 months (ANCOVA): *P=0?02, **P=0?008, ***P=0?005, ****P=0?09.
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treatment, the decrease (mgml71 was larger in the high
dose budesonide compared to the low dose budesonide
group, but this dierence did not reach statistical sig-
nificance (P=0?10). When measured as dose steps, the PC20FIG. 1. Weekly mean morning PEF-values during the low
dose (200mg) (*) and high dose (800mg) (&) budesonide
treatment. The values are presented as % predicted.FEV1 rose from 5?6 to 6?5 during the 12-week treatment in
the low dose group, and from 5?5 to 7?0 in the high dose
group, resulting in a treatment dierence of 0?5 dose steps
(P=0?15, 95% CI 70?10–1?10). When smoking was
included in the model, an interaction (P=0?07) was noted:FIG. 2. Weekly mean evening PEF-values during the low
dose (200mg) (*) and high dose (800mg) (&) budesonide
treatment. The values are presented as % predicted.
TABLE 3. Bronchial hyper-responsiveness at baseline and during the low dose (200 mg) and high dose (800 mg) inhaled
budesonide treatment
Budesonide 200mg Budesonide 800 mg
PC20 FEV1 (mg m1
71) geometric mean (range)
Baseline 1?50 (0?18–7?76) 1?44 (0?07–8?05)
6 weeks 3?02 (0?22–32) 3?95 (0?09–32)
12 weeks 2?80 (0?36–32) 3?86 (0?22–32)
PC20 FEV1 as mean dose steps (range)
Baseline 5?6 (2?5–8?0) 5?5 (1?2–8?0)
6 weeks 6?6 (2?8–10) 7?0 (1?6–10)
12 weeks 6?5 (3?5–10) 7?0 (2?8–10)
patients with PC20 FEV1 8mg m171 (%)*
6 weeks 15% 27%
12 weeks 15% 29%
Dierence between treatment groups:
*P=0?13 and P=0?09 after 6 weeks and 12 weeks, respectively (chi-square test).
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the same decrease in bronchial hyper-responsiveness as the
other subgroups.
OTHER VARIABLES
There was an identical decreasing trend in the asthmatic
symptoms and in the use of rescue medication in both
treatment groups with no statistically significant dierences
between them (Table 2). With respect to the laboratory
indices, after the 12-week treatment there was a significant
decrease in blood eosinophils in both treatment groups
(P50?001). The change was more marked in the high dose
budesonide than in the low dose budesonide group
(P=0?02). No change in S-ECP was observed in the low
dose budesonide group. In contrast, in the high dose
budesonide group a significant decrease was shown and
after 12 weeks of treatment there was a significant
dierence between the two groups (P=0?008). The changes
in S-EPX during 12-week treatment were even more
marked (P=0?005; high vs. low dose budesonide). A
statistically significant increase in S-MPO was observed in
the low-dose budesonide group. Smokers had a significantly
higher S-MPO-level compared to non-smokers, but other-
wise no significant dierences were noted in laboratory
parameters between smokers and non-smokers.
No adverse events or side eects attributable to the study
drugs were reported during the study.
Discussion
The present study shows that the same favourable clinical
response can be obtained whether the treatment is started
with a high or low dose of inhaled steroid, budesonide in
the early treatment of newly detected mild asthma. In this
respect, our study is in close agreement with a recent study
by van der Molen et al. (3). However, in our study asignificant dierence was found between the high and low
dose treatment groups in blood indices of asthmatic
inflammation. A similar trend was also observed in
bronchial hyper-responsiveness. This may indicate that
even though there was a good clinical response to the low
dose of inhaled budesonide this is not sucient to suppress
asthmatic inflammation. This is in accordance with the
study by Pedersen and Hansen (8), who stated that children
with moderate or severe asthma protection against exercise-
induced bronchoconstriction needed higher doses of
inhaled steroids than the achievement of symptom control.
It has been also shown that the eect of inhaled budesonide
on serum eosinophil markers and lung function is dose-
dependent (9). It was speculated that the full therapeutic
eect of inhaled steroid requires not only the local eect but
also some systemic eect with downregulation of the
circulating pool of eosinophils. This also supported the
study by Kraan et al. (10). They found a dose-dependent
decrease in blood eosinophils and also in bronchial hyper-
reactivity during inhaled budesonide treatment in asthmatic
patients. In a recent study of daily treatment for 1 year with
low dose inhaled budesonide 400 mg day71 no eect was
seen in blood inflammatory indices (11).
In our study, the doses of budesonide were selected on
the basis of studies which suggest that the intrabronchial
deposition of budesonide via the Turbuhaler1 device is
twice as high as that via a metered dose-inhaler (12). Thus,
the high dose of 800 mg budesonide in our study would
correspond to a dose of 1600 mg administered via a metered-
dose inhaler. This is also supported by the study of Agertoft
and Pedersen (13). They found that budesonide at half the
dose via Turbuhaler1 has the same therapeutic eect ratio
as budesonide via Nebuhaler1 in the treatment of asthma
in children.
Haahtela et al. (14) have shown that early treatment with
inhaled budesonide with a dose of 1200 mg day71 via a
metered-dose inhaler results in long-lasting control of mild
asthma. Furthermore, they found that maintenance therapy
HIGH-VS. LOW DOSE INHALED STEROID IN ASTHMA 683can usually be given with a reduced dose, but discontinua-
tion of treatment is often accompanied by exacerbation of
asthma. In the maintenance treatment of severe asthma,
Hummel et al. (15) found no dierence between the high
dose (1500mg day71) and low dose (300 mg day71)
beclomethasone. In our study the follow-up period was
relatively short and we cannot draw any conclusions about
the eect of the dose of the early-phase inhaled steroid
treatment on long-term prognosis.
Smoking by asthmatic patients may be one factor
influencing their response to inhaled steroids. In the study
by Pedersen et al. (9), smoking asthmatics were resistant to
corticosteroids. In our study, the low dose of inhaled
budesonide had no eect on bronchial hyper-reactivity or
spirometric parameters in smoking asthmatics. In contrast,
a clear positive response was seen in PEF-follow-up. The
number of smoking asthmatics was, however, relatively
small in our study as in the above-mentioned study by
Pedersen et al. (9), making it dicult to draw definite
conclusions.
In conclusion, our results show that in newly detected
asthma a favourable clinical response can be obtained with
a low dose of inhaled steroid. However, our results suggest
that the low dose of an inhaled steroid, budesonide, may
not be enough to suppress asthmatic inflammation and our
results support the view that the treatment of newly
detected asthma should be started with a high dose of
inhaled steroid even in mild cases.
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